May Hill Capital LLC lifted its position in Astrazeneca Plc (NYSE:AZN – Free Report) by 144.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,974 shares of the company’s stock after acquiring an additional 14,147 shares during the quarter. May Hill Capital LLC’s holdings in Astrazeneca were worth $4,207,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently made changes to their positions in AZN. Brighton Jones LLC raised its holdings in shares of Astrazeneca by 93.2% in the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after acquiring an additional 2,789 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Astrazeneca by 45.3% in the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock valued at $2,756,000 after acquiring an additional 11,690 shares in the last quarter. Amundi raised its holdings in shares of Astrazeneca by 54.4% in the second quarter. Amundi now owns 10,274 shares of the company’s stock valued at $731,000 after acquiring an additional 3,618 shares in the last quarter. Jump Financial LLC raised its holdings in shares of Astrazeneca by 898.4% in the second quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock valued at $2,339,000 after acquiring an additional 30,125 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its holdings in shares of Astrazeneca by 1.2% in the second quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock valued at $3,259,000 after acquiring an additional 559 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.
Astrazeneca Stock Performance
Shares of Astrazeneca stock opened at $181.62 on Friday. The company has a market capitalization of $281.67 billion, a PE ratio of 27.27, a P/E/G ratio of 1.49 and a beta of 0.26. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The company has a 50-day simple moving average of $192.38 and a two-hundred day simple moving average of $182.04. Astrazeneca Plc has a one year low of $136.16 and a one year high of $212.71.
Analyst Upgrades and Downgrades
A number of brokerages have commented on AZN. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.
Check Out Our Latest Analysis on Astrazeneca
Astrazeneca Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Recommended Stories
- Five stocks we like better than Astrazeneca
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
